Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/02/26
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take OffThe Motley Fool • 08/25/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeeking Alpha • 08/11/26
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/06/26
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y GrowthZacks Investment Research • 07/31/26
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 07/30/26
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026GlobeNewsWire • 07/16/26
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioGlobeNewsWire • 07/13/26
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHPRNewsWire • 07/02/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/26
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026GlobeNewsWire • 06/03/26
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHGlobeNewsWire • 05/27/26
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskGlobeNewsWire • 05/20/26
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 05/07/26
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/06/26